Quantitative Determination of Platelet Activating Factor in Human Plasma by LC-MS/MS Method
LI Ning,LI Shui-jun,WANG Wen-yi,WANG Yi-ping,GU Shui-ming
DOI: https://doi.org/10.3969/j.issn.1671-2838.2008.02.006
2008-01-01
Pharmaceutical Care and Research
Abstract:Objective: To establish a LC-MS/MS method for determining the concentration of platelet activating factor(PAF) in human plasma and to know the activity of lipoprotein-associated phospholipase A2(LP-PLA2),an independent risk factor for coronary artery disease(CAD) in clinical practice.Methods: After addition of PAF,the plasma sample was incubated at 37 ℃ for 10 min,then immediately pretreated with methanol for deproteinization.The supernatant was separated with liquid chromatography and detected with tandem mass spectrometry.The LP-PLA2activity was assessed from the velocity of the decrease in PAF in human plasma.Results: Good linear relation over the range of 1-50 μg/mL of PAF was obtained with regression equation y=0.284 c+0.214,r=0.999 1(n=6).At low,middle and high concentrations of quality control sample(3,20,40 μg/mL),the intra-and inter-batch RSD were 2.08%-4.75%(n=6) and 5.47%-5.86%(n=18),respectively.Accuracy was 93.50%-97.66% and recovery of PAF and febuxostat(internal standard) was 97.36%-100.8%(n=6).Sample was stable for 12 h after preparation and for 3 freeze-thaw cycles with accuracy ranging from 99.96% to 107.1%(n=6).Results of PAF determination by the developed method showed that PAF concentration of CAD group was significantly higher than that of healthy controls [(22.77±1.26) mg/mL vs(19.62±3.94) mg/mL,P0.05],which indicated a higher activity of LP-PLA2 in CAD patients than in healthy controls.Conclusion:The developed LC-MS/MS method,which is specific,accurate,reproducible,reliable and has the advantage of high throughput detection,is suitable for determining LP-PLA2 activity which can be used as a diagnostic marker for CAD and ischemic apoplexy.